H-Index
70
Scimago Lab
powered by Scopus
Clarivate
Analytics
Formerly the IP & Science
business of Thomson Reuters

Logo




eISSN: 1643-3750

Get your full text copy in PDF

Trustworthy alteration and improvement in adjuvant treatment of colon cancer.

Ali Harlak, Atilla Soran

Med Sci Monit 2006; 12(3): RA46-52

ID: 447119


Colorectal cancer is the third most common cancer both in men and womenin the United States. Advances in adjuvant treatment of colon cancer have came to consist of a successionof small improvements by large-scale clinical trials. The National Surgical Adjuvant Breast and BowelProject (NSABP) colon trials reflect the exciting history of progress in adjuvant treatment of coloncancer. Since 1977, the NSABP has successfully designed and conducted seven large-scale prospective randomizedclinical trials for colon cancers that has altered and improved the standard of care for patients withthis disease. More than 5,000 physicians, nurses, and other medical professionals at nearly 200 medicalsites from across the United States, Canada, Puerto Rico, Australia and New Zealand assist the NSABPin its mission to eliminate colorectal and breast cancers. These medical sites include several universityhospitals and many other local medical centers that treat patients from a variety of social, and economicbackgrounds contributed to the trials. The NSABP clinical trials are distinctive because of the largenumber of patients and elimination of social, cultural and economic influences. The ongoing trials ofthe NSABP should continue to provide information used to determine principals of neoadjuvant treatmentfor colon cancer. In this article we review seven prospective randomized clinical trials with their publishedresults and discuss the combined analysis of the first four trials.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree